JP2015512908A - 基礎インスリン療法 - Google Patents

基礎インスリン療法 Download PDF

Info

Publication number
JP2015512908A
JP2015512908A JP2015502348A JP2015502348A JP2015512908A JP 2015512908 A JP2015512908 A JP 2015512908A JP 2015502348 A JP2015502348 A JP 2015502348A JP 2015502348 A JP2015502348 A JP 2015502348A JP 2015512908 A JP2015512908 A JP 2015512908A
Authority
JP
Japan
Prior art keywords
insulin
diabetes
patient
risk
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015502348A
Other languages
English (en)
Japanese (ja)
Inventor
ピーター・ジョンストン
ハーツェル・ガースタイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2015512908A publication Critical patent/JP2015512908A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2015502348A 2012-03-28 2013-03-28 基礎インスリン療法 Ceased JP2015512908A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261616768P 2012-03-28 2012-03-28
US61/616,768 2012-03-28
US201261619641P 2012-04-03 2012-04-03
US61/619,641 2012-04-03
US201261624598P 2012-04-16 2012-04-16
US61/624,598 2012-04-16
US201261645909P 2012-05-11 2012-05-11
US61/645,909 2012-05-11
US201261701911P 2012-09-17 2012-09-17
US61/701,911 2012-09-17
PCT/EP2013/056661 WO2013144273A1 (en) 2012-03-28 2013-03-28 Basal insulin therapy

Publications (1)

Publication Number Publication Date
JP2015512908A true JP2015512908A (ja) 2015-04-30

Family

ID=48044781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502348A Ceased JP2015512908A (ja) 2012-03-28 2013-03-28 基礎インスリン療法

Country Status (13)

Country Link
US (1) US20150065421A1 (enExample)
EP (1) EP2830650A1 (enExample)
JP (1) JP2015512908A (enExample)
KR (1) KR20150001757A (enExample)
CN (1) CN104334183A (enExample)
AU (1) AU2013241776B2 (enExample)
CA (1) CA2865823A1 (enExample)
HK (1) HK1201155A1 (enExample)
IN (1) IN2014KN02335A (enExample)
MX (1) MX2014011687A (enExample)
RU (1) RU2014143271A (enExample)
SG (1) SG11201405433XA (enExample)
WO (1) WO2013144273A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505503A (ja) * 2015-12-23 2019-02-28 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 心臓の代謝性に対するランタスの効果

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46890A (fr) 2016-11-28 2021-04-28 Novo Nordisk As Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
EP3544683A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
US20190357853A1 (en) * 2018-05-24 2019-11-28 Lizheng Shi Diabetes risk engine and methods thereof for predicting diabetes progression and mortality

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515625A (ja) * 2003-01-14 2006-06-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド 前糖尿病患者および２型糖尿病患者における心血管系の罹病率および死亡率を低下させるための長時間作用型インスリン

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012502524A1 (en) * 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515625A (ja) * 2003-01-14 2006-06-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド 前糖尿病患者および２型糖尿病患者における心血管系の罹病率および死亡率を低下させるための長時間作用型インスリン

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIABETES CARE, vol. 30, no. 8, JPN6017000995, 2007, pages 2001 - 2002, ISSN: 0003480691 *
PUBMED ABSTRACT 12783637, JPN6017000996, 2003, ISSN: 0003480692 *
VALUE HEALTH, vol. Vol.15, No.1 Suppl, JPN6017000994, February 2012 (2012-02-01), pages 56 - 59, ISSN: 0003480690 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505503A (ja) * 2015-12-23 2019-02-28 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 心臓の代謝性に対するランタスの効果
JP7138565B2 (ja) 2015-12-23 2022-09-16 サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 心臓の代謝性に対するランタスの効果

Also Published As

Publication number Publication date
KR20150001757A (ko) 2015-01-06
RU2014143271A (ru) 2016-05-20
SG11201405433XA (en) 2014-10-30
WO2013144273A1 (en) 2013-10-03
AU2013241776A1 (en) 2014-10-16
CN104334183A (zh) 2015-02-04
IN2014KN02335A (enExample) 2015-05-01
EP2830650A1 (en) 2015-02-04
HK1201155A1 (en) 2015-08-28
US20150065421A1 (en) 2015-03-05
MX2014011687A (es) 2015-05-11
AU2013241776B2 (en) 2017-11-02
CA2865823A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
Pfeiffer et al. The treatment of type 2 diabetes
Janez et al. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group
Sweitzer et al. Preoperative care for cataract surgery: the Society for Ambulatory Anesthesia position statement
Scobie et al. Fast facts: diabetes mellitus
Yandrapalli et al. Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus
AU2013241776B2 (en) Basal insulin therapy
JP2019535791A (ja) 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク
US20210000792A1 (en) Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
Monteiro et al. Effect of empagliflozin beyond glycemic control: cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease
Idrogo et al. Diabetes in the Hispanic population: high risk warrants targeted screening and treatment
JP2020523408A5 (enExample)
Azeez Present State and Perspectives of Type 2 Diabetes Management
Dhatariya et al. In‐Hospital Treatment and Surgery in People With Diabetes
Hudson et al. Diabetes in older adults
Class et al. Patent application title: BASAL INSULIN THERAPY Inventors: Peter Johnston (Bridgewater, NJ, US) Hertzel Gerstein (Hamilton, CA) Hertzel Gerstein (Hamilton, CA)
Cherian et al. Therapeutic implications of diabetes in cardiovascular disease
Das et al. Pathophysiology and Clinical Therapeutic Aspects of Diabetes
Valdez et al. Long term evaluation of intensive insulin therapy in patients with type 2 diabetes mellitus
Tsoutsouki et al. A year in diabetic nephropathy
Wong et al. Navigating Hypoglycemia in Diabetes Care: Clinical Management Strategies and Glucagon Treatment Options
Sia Pharmacologic management of diabetes in older adults
Shelbaya et al. Patterns and Changes in the Treatment of Patients with Type II Diabetes Mellitus in Egypt: The DISCOVER Program
Jang et al. The Early Detection and Managements of Euglycemic Diabetic Ketoacidosis Based on a Rapid Response System: Two Case Reports
White et al. Drugs for diabetes: part 9 prescribing for patients with cardiac disease
Srinivasan et al. Glycaemic management of type 2 diabetes

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160314

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170905

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171003

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20180227